New Enterprise Associates

New Enterprise Associates, Inc. is a private equity and venture capital firm established in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investments across various stages of company development, including seed, start-up, early stage, and later stage, with a focus on sectors such as information technology, healthcare, and energy technology. NEA's investment strategy encompasses a wide range of industries, including consumer internet, software, biotechnology, medical devices, and alternative energy. With over $19 billion in cumulative committed capital, the firm has a notable track record, having participated in more than 210 portfolio company IPOs and over 360 acquisitions. NEA aims to invest between $0.05 million and $20 million, targeting both domestic and international markets, particularly in Asia and the Americas.

Michael James Barrett

Partner Emeritus

Kate Barrett

Marketing Partner

Peter J. Barris

Chairman

Ronald D. Bernal

Venture Partner

Ron Bernal

Venture Partner

Tak Cheung

Partner

Philip Chopin

Managing Director

Louis Citron

Chief Administrative Officer and Chief Legal Officer

Robert Croce

Venture Advisor

Bala Deshpande

Sr. Managing Director, India

Lexi Eisenberg

Associate

Anthony A. Florence

Managing General Partner, Technology

Tony Florence

General Partner

Carol Gallagher

Advisor

Tracy Howe

Investment Professional

Suzanne Hooper King

Partner

Liza Landsman

General Partner

Michael Li

Investor

Tiffany Luck

Partner

Joshua Makower

General Partner

Edward T. Mathers

Partner

John Nehra

Retired Special Partner

Michael D. O'Dell

Venture Partner

Santhosh Palani

Principal

Greg Papadopoulos

Venture Partner

Michele Park

Partner

Arno Allan Penzias

Venture Advisor

Eugene A. Trainor

COO

James G. Treybig

Venture Advisor

Paul Walker

General Partner

Harry Weller

Former General Partner

Past deals in TMT

Moximed

Series C in 2022
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

Tune Therapeutics

Series A in 2021
Tune Therapeutics is focused on developing innovative cell and gene therapies that utilize epigenetic programming to address serious diseases. By harnessing the potential of the epigenome, the company aims to create new therapeutic pathways that modify biological functions without changing the underlying DNA sequence. This approach seeks to provide effective treatments for complex and widespread diseases, positioning Tune Therapeutics at the forefront of advancements in epigenetic medicine.

TAE Technologies

Venture Round in 2021
TAE Technologies is leveraging proprietary science and engineering to tackle the world’s biggest challenges. Their core mission is to create a new source of clean energy – one that’s powered by nature’s own processes and produces no harmful byproducts. Their groundbreaking work has led to industry-wide advances in accelerator and plasma physics, and acted as a catalyst for adjacent innovations based on their results. With 20 years of focused research, TAE Technologies is on a purposeful path to commercial fusion energy and pioneering sustainable solutions for a better tomorrow.

ThreatQuotient

Venture Round in 2021
ThreatQuotient is a threat intelligence platform (TIP) that centrally manages and correlates unlimited external sources with all internal security and analytics solutions for contextual, operationalized intelligence in a single pane of glass. ThreatQ is also the first TIP to provide Indicator Nurturing, which goes beyond enrichment to help customers tailor indicators of compromise (IOCs) more specifically to their infrastructure. Headquartered in Northern Virginia, ThreatQuotient was founded in 2013 by two former security operations analysts to provide organizations the ability to correlate with confidence.

ThreatQuotient

Debt Financing in 2021
ThreatQuotient is a threat intelligence platform (TIP) that centrally manages and correlates unlimited external sources with all internal security and analytics solutions for contextual, operationalized intelligence in a single pane of glass. ThreatQ is also the first TIP to provide Indicator Nurturing, which goes beyond enrichment to help customers tailor indicators of compromise (IOCs) more specifically to their infrastructure. Headquartered in Northern Virginia, ThreatQuotient was founded in 2013 by two former security operations analysts to provide organizations the ability to correlate with confidence.

Monte Rosa Therapeutics

Series C in 2021
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

MindTickle

Series D in 2020
MindTickle Interactive Media Pvt Ltd. provides a social learning platform for organizations and corporations in various industries. Its platform enables businesses, trainers, and individuals to transform their existing online content into an interactive learning experience; use game mechanics, such as points, medals, badges, and leader boards to increase learner motivation and engagement; create learner engagement and peer-to-peer learning by leveraging the power of social mechanics; and measure and track the effectiveness Web-based training programs through real-time charts and dashboards. The company’s platform is used for new hire orientation, policy refreshment, and employee engagement applications. MindTickle Interactive Media Pvt Ltd. was founded in 2011 and is based in Pune, India.

Monte Rosa Therapeutics

Series B in 2020
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

Monte Rosa Therapeutics

Series A in 2020
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

MindTickle

Series B in 2017
MindTickle Interactive Media Pvt Ltd. provides a social learning platform for organizations and corporations in various industries. Its platform enables businesses, trainers, and individuals to transform their existing online content into an interactive learning experience; use game mechanics, such as points, medals, badges, and leader boards to increase learner motivation and engagement; create learner engagement and peer-to-peer learning by leveraging the power of social mechanics; and measure and track the effectiveness Web-based training programs through real-time charts and dashboards. The company’s platform is used for new hire orientation, policy refreshment, and employee engagement applications. MindTickle Interactive Media Pvt Ltd. was founded in 2011 and is based in Pune, India.

ThreatQuotient

Series C in 2017
ThreatQuotient is a threat intelligence platform (TIP) that centrally manages and correlates unlimited external sources with all internal security and analytics solutions for contextual, operationalized intelligence in a single pane of glass. ThreatQ is also the first TIP to provide Indicator Nurturing, which goes beyond enrichment to help customers tailor indicators of compromise (IOCs) more specifically to their infrastructure. Headquartered in Northern Virginia, ThreatQuotient was founded in 2013 by two former security operations analysts to provide organizations the ability to correlate with confidence.

Moximed

Series C in 2017
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

The Players' Tribune

Series B in 2017
The Players' Tribune (TPT) is a first-of-its-kind content and technology platform that was developed by athletes for athletes to connect them with fans through the power of storytelling. By giving athletes the tools to create truly personal content and tell their stories, The Players’ Tribune is reimagining the world of sports and culture through the player’s point of view. More than 2,000 athletes have contributed to the platform through impactful and powerful long and short-form stories, video series, and audio. It was founded by Derek Jeter in 2014, TPT provides unique insight into the daily sports conversation and brings fans closer than ever to the games they love.
Trillium Therapeutics Inc. is a clinical-stage immuno-oncology company based in Mississauga, Canada, focused on developing therapies for cancer treatment. Its leading program, TTI-621, is a SIRPaFc fusion protein designed to inhibit the CD47 signal, currently undergoing Phase I clinical trials for advanced relapsed or refractory hematologic malignancies, solid tumors, and mycosis fungoides. The company is also advancing TTI-622, another SIRPaFc protein in Phase I trials, and TTI-10001, a small molecule stimulator of interferon genes agonist in the discovery phase aimed at enhancing tumor immunity. Trillium Therapeutics, originally founded in 2004 and previously known as Stem Cell Therapeutics Corp., specializes in the discovery and development of protein therapeutics, including monoclonal antibodies and peptides, with a focus on cancer and other therapeutic areas.

ThreatQuotient

Series B in 2016
ThreatQuotient is a threat intelligence platform (TIP) that centrally manages and correlates unlimited external sources with all internal security and analytics solutions for contextual, operationalized intelligence in a single pane of glass. ThreatQ is also the first TIP to provide Indicator Nurturing, which goes beyond enrichment to help customers tailor indicators of compromise (IOCs) more specifically to their infrastructure. Headquartered in Northern Virginia, ThreatQuotient was founded in 2013 by two former security operations analysts to provide organizations the ability to correlate with confidence.

Moximed

Series B in 2016
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

ThreatQuotient

Series A in 2015
ThreatQuotient is a threat intelligence platform (TIP) that centrally manages and correlates unlimited external sources with all internal security and analytics solutions for contextual, operationalized intelligence in a single pane of glass. ThreatQ is also the first TIP to provide Indicator Nurturing, which goes beyond enrichment to help customers tailor indicators of compromise (IOCs) more specifically to their infrastructure. Headquartered in Northern Virginia, ThreatQuotient was founded in 2013 by two former security operations analysts to provide organizations the ability to correlate with confidence.

MindTickle

Series A in 2015
MindTickle Interactive Media Pvt Ltd. provides a social learning platform for organizations and corporations in various industries. Its platform enables businesses, trainers, and individuals to transform their existing online content into an interactive learning experience; use game mechanics, such as points, medals, badges, and leader boards to increase learner motivation and engagement; create learner engagement and peer-to-peer learning by leveraging the power of social mechanics; and measure and track the effectiveness Web-based training programs through real-time charts and dashboards. The company’s platform is used for new hire orientation, policy refreshment, and employee engagement applications. MindTickle Interactive Media Pvt Ltd. was founded in 2011 and is based in Pune, India.

The Players' Tribune

Series A in 2015
The Players' Tribune (TPT) is a first-of-its-kind content and technology platform that was developed by athletes for athletes to connect them with fans through the power of storytelling. By giving athletes the tools to create truly personal content and tell their stories, The Players’ Tribune is reimagining the world of sports and culture through the player’s point of view. More than 2,000 athletes have contributed to the platform through impactful and powerful long and short-form stories, video series, and audio. It was founded by Derek Jeter in 2014, TPT provides unique insight into the daily sports conversation and brings fans closer than ever to the games they love.

Moximed

Series B in 2015
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

Traitify

Debt Financing in 2013
Traitify is a personality data company building the personality data genome for the employment marketplace. The company uses human interaction with images to create the fastest validated talent assessments in the market. Its platform includes the fastest talent assessments in the world multiple image-based behavioral assessments that are scientifically-validated and take 90 seconds to 2 minutes to complete on a mobile device and have 95% or greater completion rates. Companies use their platform to create a great candidate and employee experiences. Imagine giving value back to the candidates in the talent pool by making personalized recommendations for what job to apply for. Or generating personalized content to share back with candidates to create ongoing engagement, all based on their unique personality traits. Companies with great employment brands create reciprocity with candidates and employees alike.

Motus Therapeutics

Series B in 2012
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

Motus Therapeutics

Series B in 2012
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

Moximed

Venture Round in 2012
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

Motus Therapeutics

Series A in 2010
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

Motus Therapeutics

Series A in 2010
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

TAE Technologies

Venture Round in 2010
TAE Technologies is leveraging proprietary science and engineering to tackle the world’s biggest challenges. Their core mission is to create a new source of clean energy – one that’s powered by nature’s own processes and produces no harmful byproducts. Their groundbreaking work has led to industry-wide advances in accelerator and plasma physics, and acted as a catalyst for adjacent innovations based on their results. With 20 years of focused research, TAE Technologies is on a purposeful path to commercial fusion energy and pioneering sustainable solutions for a better tomorrow.

Teneros

Series D in 2008
Teneros is a Mountain View, CA based company that focuses on comprehensive "application and data continuity" for Microsoft Exchange e-mail servers, keeping Microsoft Exchange crashes, technology failures, and site-wide outages from taking down a company's messaging system.

Telsima

Debt Financing in 2007
Telsima Corp. develops and markets base station and subscriber station systems and network management software for the WiMAX telecommunications market. The company offers mobile WiMAX, WiMAX certified broadband wireless access, and mobility solutions. Telsima Corp. was formerly known as Kinera, Inc. The company was founded in 1999 and is based in Sunnyvale, California with offices and facilities in Bangalore, Gurgaon, and Mumbai, India; and Trzin-Ljubljana, Slovenia.

Telsima

Venture Round in 2007
Telsima Corp. develops and markets base station and subscriber station systems and network management software for the WiMAX telecommunications market. The company offers mobile WiMAX, WiMAX certified broadband wireless access, and mobility solutions. Telsima Corp. was formerly known as Kinera, Inc. The company was founded in 1999 and is based in Sunnyvale, California with offices and facilities in Bangalore, Gurgaon, and Mumbai, India; and Trzin-Ljubljana, Slovenia.

Teneros

Series C in 2006
Teneros is a Mountain View, CA based company that focuses on comprehensive "application and data continuity" for Microsoft Exchange e-mail servers, keeping Microsoft Exchange crashes, technology failures, and site-wide outages from taking down a company's messaging system.

Telsima

Series C in 2005
Telsima Corp. develops and markets base station and subscriber station systems and network management software for the WiMAX telecommunications market. The company offers mobile WiMAX, WiMAX certified broadband wireless access, and mobility solutions. Telsima Corp. was formerly known as Kinera, Inc. The company was founded in 1999 and is based in Sunnyvale, California with offices and facilities in Bangalore, Gurgaon, and Mumbai, India; and Trzin-Ljubljana, Slovenia.

eNeura

Series B in 2005
eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.

T-RAM Semiconductor

Series C in 2005
T-RAM Semiconductor is a fabless semiconductor company that has developed an innovative process based on TCCT (Thin-Capacitively-Coupled-Thyristor) technology, which produces a memory cell one-fourth to one-eighth the size of competing 6T-SRAM (Six Transistor-Static Random Access Memory) memory technology. T-RAM Semiconductor is using its proprietary TCCT technology advantage to produce both higher density and lower cost High Performance Synchronous SRAM's targeting the discrete and embedded memory needs of high- performance computer servers, networking, and telecom.

Teneros

Series B in 2005
Teneros is a Mountain View, CA based company that focuses on comprehensive "application and data continuity" for Microsoft Exchange e-mail servers, keeping Microsoft Exchange crashes, technology failures, and site-wide outages from taking down a company's messaging system.

Teneros

Series A in 2004
Teneros is a Mountain View, CA based company that focuses on comprehensive "application and data continuity" for Microsoft Exchange e-mail servers, keeping Microsoft Exchange crashes, technology failures, and site-wide outages from taking down a company's messaging system.

Tasman Networks

Venture Round in 2004
Tasman Networks is a manufacturer of Multi-service edge router.

Iomai Corporation

Series C in 2003
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was incorporated in 1997 and is based in Gaithersburg, Maryland. Intercell USA, Inc. was formerly known as Iomai Corporation. As a result of the acquisition of Iomai Corporation by Intercell Ag, Iomai Corporation's name was changed. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Intercell Biomedical Research & Development AG.

Tasman Networks

Venture Round in 2002
Tasman Networks is a manufacturer of Multi-service edge router.

T-RAM Semiconductor

Series B in 2002
T-RAM Semiconductor is a fabless semiconductor company that has developed an innovative process based on TCCT (Thin-Capacitively-Coupled-Thyristor) technology, which produces a memory cell one-fourth to one-eighth the size of competing 6T-SRAM (Six Transistor-Static Random Access Memory) memory technology. T-RAM Semiconductor is using its proprietary TCCT technology advantage to produce both higher density and lower cost High Performance Synchronous SRAM's targeting the discrete and embedded memory needs of high- performance computer servers, networking, and telecom.

eNeura

Series A in 2002
eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.

TestMart

Series C in 2000
- TestMart, dba GSAMart, is the #1 Test Equipment Reseller to the U.S. Government. - Holds the GSA Schedule 66 (Contract #GS24F0066M) and partners with over 100 manufacturers. - Carries over 200,000 SKUs that are GSA-compliant. - Over 15 years experience working with the U.S. government contractors, buyers, and end-users.

Altitun

Series B in 1999
Altitun AB provides a full tunable laser product line, designed to help systems vendors and carriers reduce costs today and drive the all-optical networks of tomorrow. Altitun is the provider of the world’s most complete tunable laser product line.

Tasman Networks

Venture Round in 1999
Tasman Networks is a manufacturer of Multi-service edge router.